HUNTSVILLE, Ala., April 15 /PRNewswire/ -- Open Biosystems, Inc.,
focused on the commercialization of leading-edge life science research
tools for drug discovery, today announced the availability of new
Decode(TM) RNAi viral screening pools for multiplexed RNAi screens. This
novel offering allows researchers access to genome-scale RNAi screens and
the ability to rapidly screen through thousands of genes at a time
utilizing PCR and traditional sequencing.
(Logo: http://www.newscom.com/cgi-bin/prnh/20070423/CLM143LOGO )
The first Decode RNAi viral screening set has been created using Open
Biosystems' GIPZ lentiviral shRNAmir library validated in its ability to
produce effective knockdown even when expressed from a single integration
event in target cells. This pooled screening set targets the entire human
genome in a ready-to-use lentiviral pool format, extending RNAi screening
to primary and non-dividing cells. The Decode RNAi product will be expanded
to include shRNAmir pools providing choices in promoters, fluorescent
markers and type of viral vector increasing the ability to perform genome
scale RNAi screening in all cell types and assays.
Two recent publications from Dr. Greg Hannon and Dr. Steve Elledge,
developers of the shRNAmir technology for RNAi, display the power of
multiplexed RNAi screening using shRNAmir pools. They were able to identify
genes that are selectively required by certain cancer cells but not by
normal cells. Identification of selective vulnerabilities in specific
cancer cells is key to the development of alternative cancer therapeutics.
Dr. Ricky Johnstone, Group Leader of Gene Regulation at the Peter
MacCallum Cancer Center said, "As beta users of the Open Biosystems' Decode
RNAi viral pools, we are very happy with its convenient format, knockdown
performance in multiplexed RNAi screens, as well as, its ability to
transduce many different cell lines. Researchers at the Peter Mac are very
excited about the possibilities of being able to comb through thousands of
genes at a time to further our understanding of cancer biology and
ultimately the search for novel cancer therapeutics."
"The Decode RNAi pooled libraries take RNAi screening to the bench
top," said Troy Moore, Chief Technology Officer at Open Biosystems. "Until
now, genome-scale RNAi screens could only be performed by large labs or
institutions that had spent millions of dollars in equipment and reagents.
The Decode RNAi viral screening pools makes it possible for individual
laboratories to do these studies without the labor and high cost of
robotics. Open Biosystems continues to arm the research community with the
RNAi tools necessary to propel research efforts to the next level. The
Decode RNAi viral screening pools give researchers at all levels access to
genome-scale RNAi screens that may lead to novel therapeutics and treatment
options for human disease."
Decode RNAi viral screening pools are available immediately as single
use screening kits for positive selection screening. For additional
information, please contact email@example.com.
About Open Biosystems
Open Biosystems, Inc. develops manufactures and markets genomic
research tools to scientists and researchers in corporate, academic and
government laboratories. These research tools provide investigators with
standardized high-quality genes, RNAi and antibodies for interrogating gene
function in relation to oncology, neuroscience and metabolic disorders.
Founded in 2001, Open Biosystems is headquartered in Huntsville, Alabama.
For more information and details for ordering, please visit:
SOURCE Open Biosystems, Inc.